New kidney transplant drug effective in humans, UCSF study finds
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the <i>American Journal of Transplantation</i> that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.